New AI-driven collaboration aims to accelerate CNS therapeutic development and commercial translation from discovery to market.
Key Takeaways
- Collaboration targets a mass-market central nervous system indication with an innovative mechanism of action
- Insilico can receive up to approximately 1.2 billion RMB in milestone payments plus royalties
- CMS will contribute experienced R&D, clinical development, regulatory, and commercialization capabilities